TY  - JOUR
AU  - Gómez-Arias, Pedro Jesús
AU  - Gómez-García, Francisco
AU  - Hernández-Parada, Jorge
AU  - Montilla-López, Ana María
AU  - Ruano, Juan
AU  - Parra-Peralbo, Esmeralda
PY  - 2021
DO  - 10.1007/s13555-021-00517-9
SN  - 2193-8210
UR  - https://hdl.handle.net/10668/28261
T2  - Dermatology and therapy
AB  - Type I interferon (IFN)-mediated monogenic autoinflammatory disorders (interferonopathies) are childhood-onset rare multisystemic diseases with limited treatment options. The Janus kinase (JAK) inhibitors are promising potential therapeutic candidates...
LA  - en
KW  - Autoinflammatory diseases
KW  - Baricitinib
KW  - CANDLE
KW  - Familial chilblain lupus
KW  - Interferon pathway
KW  - JAK inhibitors
KW  - Ruxolitinib
KW  - SAVI
KW  - Tofacitinib
TI  - Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review.
TY  - research article
VL  - 11
ER  -